Precision Biosciences (DTIL) Gains from Investment Securities (2018 - 2026)
Precision Biosciences (DTIL) reported Gains from Investment Securities of $4000.0 for Q1 2026, up 144.44% year-over-year from $1636.4 in Q1 2025, and up 101.03% quarter-over-quarter from -$390000.0 in Q4 2025.
Precision Biosciences (DTIL) Gains from Investment Securities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Gains from Investment Securities data on file, last reported at $4000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $4000.0, up 144.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$408000.0 (up 52.83% YoY), and the FY2025 annual result was -$421000.0, down 211.8% from the prior year.
- Gains from Investment Securities rose to $4000.0 in Q1 2026 per DTIL's latest filing, from -$390000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $13.8 million in Q3 2022 and troughed at -$626000.0 in Q4 2023.
- A 5-year average of $2.4 million and a median of $14599.0 in 2024 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 1635.81% in 2023 and fell as far as 1204.17% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at -$48000.0 in 2022, then tumbled by 1204.17% to -$626000.0 in 2023, then surged by 70.93% to -$182000.0 in 2024, then sank by 114.29% to -$390000.0 in 2025, then soared by 101.03% to $4000.0 in 2026.
- Business Quant data shows DTIL's Gains from Investment Securities at $4000.0 in Q1 2026, -$390000.0 in Q4 2025, and $3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | -390,000.00 |
| Dec 31, 2025 | -390,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Dec 31, 2024 | -182,000.00 |
| Dec 31, 2024 | -182,000.00 |
| Sep 30, 2024 | 23,427.00 |
| Sep 30, 2024 | 23,427.00 |
| Jun 30, 2024 | 348,794.00 |
| Jun 30, 2024 | 348,794.00 |
| Mar 31, 2024 | 14,599.00 |
| Mar 31, 2024 | 14,599.00 |
| Dec 31, 2023 | -626,000.00 |
| Dec 31, 2023 | -626,000.00 |